化疗治疗的复发或转移性头颈癌患者的新预后模型:ECOG-ACRIN E1305分析
该研究为ECOG-ACRIN E1305 III期试验的事后分析,纳入403例接受含铂双药化疗联合或不联合贝伐珠单抗一线治疗的复发或转移性头颈鳞癌患者。新预后模型包含4个危险因素:ECOG体能状态(1 vs 0)、原发肿瘤部位(其他 vs 口咽)、骨或肝转移、既往头颈部放疗。危险因素≤2个(n=249)与>2个(n=154)的患者中位OS分别为15.2个月和7.6个月(HR 2.14,95%CI 1.73-2.66,P<0.0001)。
要点
- 新预后模型含4个基线可评估的临床危险因素。
- 危险因素≤2个患者中位OS 15.2个月,>2个患者7.6个月。
- HR 2.14(95%CI 1.73-2.66,P<0.0001)支持模型区分预后。
核心结论
- 新提出的模型包含4个基线可评估的临床预后因素,类似模型有潜力改进试验设计和优化复发或转移性头颈鳞癌患者的分层。
研究设计与样本
- ECOG-ACRIN E1305 III期临床试验的事后分析,纳入所有接受含铂双药化疗联合或不联合贝伐珠单抗一线治疗的复发或转移性头颈鳞癌患者,共403例。
主要发现
- 整个研究队列的中位OS为11.8个月(90%CI 10.6-13.2)。
- 新预后模型包含4个危险因素:ECOG体能状态(1 vs 0)、原发肿瘤部位(其他 vs 口咽)、骨或肝转移、既往头颈部放疗。
- 危险因素≤2个(n=249)与>2个(n=154)的患者中位OS分别为15.2个月和7.6个月(HR 2.14,95%CI 1.73-2.66,P<0.0001)。
关键数值与推荐
- 危险因素≤2个组中位OS 15.2个月,>2个组中位OS 7.6个月(HR 2.14,95%CI 1.73-2.66,P<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: For patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) periodic reassessment of prognostic factors provides valuable information that can aid in patient stratification. PATIENTS AND METHODS: This post hoc analysis included all patients with R/M HNSCC enrolled in the ECOG-ACRIN E1305 phase III clinical trial who received first-line treatment with platinum-containing chemotherapy doublet with or without bevacizumab. Overall survival (OS) was estimated using the Kaplan-Meier method. Prognostic factors for OS were identified using univariate and multivariable analyses. A new prognostic model for OS was built retaining the prognostic factors which were significant in the final multivariable analysis (P < 0.05). RESULTS: All 403 study participants were included in the analysis. The median OS in the whole study cohort was 11.8 months (90% confidence intervals [CI], 10.6-13.2). The new prognostic model for OS comprised four risk factors (ECOG performance status [1 versus 0], primary tumor location [other versus oropharynx], presence of bone or liver metastasis, and prior radiation to the head and neck); patients with ≤ 2 (n = 249) and > 2 risk factors (n = 154) had a median OS of 15.2 and 7.6 months, respectively (Hazard ratio, 2.14; 95% CI, 1.73-2.66; P < 0.0001). CONCLUSIONS: The new proposed model includes 4 clinical prognostic factors that can be readily assessed at baseline. Similar models have the potential to improve trial design and optimize stratification of patients with R/M HNSCC.
引用
- Argiris A, Flamand Y, Savvides P, et al. A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305. Eur J Cancer. 2023. PMID: 38215573. doi:10.1016/j.ejca.2023.113509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。